RESEARCH HIGHLIGHT

Nivolumab plus ipilimumab: a potential regimen to rewrite treatment guidelines for ESCC

Yuejun Luo1,2, Nan Sun1,2✉ and Jie He1,2✉

Signal Transduction and Targeted Therapy (2022) 7:169; https://doi.org/10.1038/s41392-022-01022-x

The recent research published in The New England Journal of Medicine by Y. Doki et al. has reported the interim findings from the CheckMate 648, which is an international, multi-center, open-label, and randomized phase 3 clinical trial to explore the role of dual immune checkpoints inhibitors combination for patients with advanced esophageal squamous cell carcinoma (ESCC). This study evaluated the efficacy and safety of the combination of PD-1 and CTLA-4 inhibitors for patients with advanced ESCC, aiming to provide some enlightenment for advanced ESCC treatment.

Patients recruited in the CheckMate 648 were diagnosed with advanced, metastatic, or recurrent ESCC. The details of enrollment criterion included age more than 18-year, naïve to systemic therapy for advanced disease, measurable disease, pathological identification of ESCC or esophageal adenocarcinoma. All 970 patients were randomly divided into nivolumab plus chemotherapy, nivolumab plus ipilimumab, and chemotherapy alone groups for 1:1:1. The primary endpoints included progression-free survival (PFS) and overall survival (OS), while objective response rate was the secondary endpoint. Compared with chemotherapy alone group (median PFS: 5.6 months, median OS: 10.7 months), the nivolumab plus chemotherapy group demonstrated longer PFS (median PFS: 5.8 months) and OS (median OS: 13.2 months) in all populations, and the nivolumab plus ipilimumab groups exhibited favorable OS (median OS: 13.2 months) in all populations, while patients with negative PD-L1 expression seemed to benefit little from this combination, and a constant follow-up is needed to observe whether patients with negative PD-L1 will eventually benefit from this regimen. Therefore, chemotherapy still has a proper place in the treatment of advanced ESCC, especially PD-1 inhibitor combined with chemotherapy is the most widely applied chemotherapy regimen.

The authors failed to explore more subgroups analyses except for PD-L1. Previous studies have observed patients with blood-Tumor burden mutation (bTMB) ≥20 mut/Mb or high TMB regardless of PD-L1 expression significantly benefited from the PD-L1 plus CTLA-4 inhibitors in lung cancer. In metastatic colorectal cancer, patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) demonstrated a durable clinical benefit from this dual inhibitors regimen. We speculated that bTMB, TMB, and MSI-H/dMMR may be potential biomarkers of this combination in advanced ESCC. The robust biomarkers are warranted to select patients sensitive to dual inhibitors, maximizing their survival benefits and avoiding serious adverse effects of chemotherapy. Moreover, whether this dual immune checkpoint blockades regimen can be applied to the other treatment period of ESCC, for example, as neoadjuvant therapy to improve pathological complete rates for patients with PD-L1 expression ≥1%, or higher bTMB and TMB, or MSI-H/dMMR?

Novel anti-tumor drugs are being vigorously developed. In the future, we believe that newly developed drugs may be available in combination with current immune checkpoint inhibitors to help patients with ESCC achieve a favorable prognosis and quality of life.
| Cancer type                  | Year | Patients | Therapy                        | Primary outcomes                  | Grade 3–4 adverse events rate | Treatment-related deaths |
|-----------------------------|------|----------|--------------------------------|-----------------------------------|-------------------------------|--------------------------|
| **Esophagogastric cancer**  | 2018 | 160      | N 3mg/Kg                       | ORR: 12% (95 CI%: 5–23%)          | 17%                           | 0/59                     |
|                            |      |          | N 1mg/Kg plus I 3mg/Kg         | ORR: 24% (95 CI%: 13–39%)         | 47%                           | 0/49                     |
|                            |      |          | N 3mg/Kg plus I 1mg/Kg         | ORR: 8% (95 CI%: 2–19%)           | 27%                           | 1/52                     |
| **mUC** (Checkmate 032)    | 2019 | 274      | N 3mg/Kg                       | ORR: 25.6% (95 CI%: 16.4–36.8%)  | 26.9%                         | 1/78                     |
|                            |      |          | N 1mg/Kg plus I 3mg/Kg         | ORR: 38% (95 CI%: 28.1–48.8%)    | 39.1%                         | 0/92                     |
|                            |      |          | N 3mg/Kg plus I 1mg/Kg         | ORR: 26.9% (95 CI%: 18.7–36.5%)  | 30.8%                         | 1/104                    |
| **SCLC** (Checkmate 032)   | 2020 | 243      | N                              | ORR: 11.6% (95 CI%: 6.9–17.9%)   | 12.9%                         | 1/147                    |
|                            |      |          | N plus I                       | ORR: 21.9% (95 CI%: 14.1–31.5%)  | 37.5%                         | 3/96                     |
| **mCRC** (Checkmate 142)   | 2018 | 193      | N                              | ORR: 31% (95 CI%: 20.8–42.9%)    | 20.3%                         | 0/74                     |
|                            |      |          | N plus I                       | ORR: 55% (95 CI%: 45.2–63.8%)    | 32%                           | 0/119                    |
| **Melanoma** (Checkmate 067)| 2021 | 945      | N                              | OS: 36.9 months (95 CI%: 28.2–58.7) | 22%                           | 1/313                    |
|                            |      |          | I                              | OS: 19.9 months (95 CI%: 16.8–24.6) | 28%                           | 1/311                    |
|                            |      |          | N plus I                       | OS: 72.1 months (95 CI%: 38.2–not reached) | 59%                           | 2/13                      |
| **OCSCC** (NCT02919683)    | 2020 | 29       | N                              | MPR rate: 7.1% (1/14)            | 14.3%                         | 0/14                     |
|                            |      |          | N plus I                       | MPR rate: 20% (3/15)             | 33.3%                         | 0/15                     |
| **NSCLC** (NCT03158129)    | 2021 | 44       | N                              | MPR rate: 22% (5/23)             | 13%                           | 1/23                     |
|                            |      |          | N plus I                       | MPR rate: 38% (8/21)             | 10%                           | 0/21                     |
| **EOC** (NCT02498600)      | 2020 | 100      | N                              | ORR: 12.2%                      | 33%                           | 0/49                     |
|                            |      |          | N plus I                       | ORR: 31.4%                      | 49%                           | 0/51                     |
| **MPM** (NCT02716272)      | 2021 | 125      | N                              | 12-week DCR: 39.7% (95 CI%: 27.6–51.8%) | 14.3%                         | 0/63                     |
|                            |      |          | N plus I                       | 12-week DCR: 51.6% (95 CI%: 39.2–64.1%) | 26.2%                         | 3/61                     |
| **Metastatic sarcoma**      | 2018 | 85       | N                              | ORR: 5% (92 CI%: 1–15%)          | 7%                            | 0/43                     |
|                            |      |          | N plus I                       | ORR: 16% (92 CI%: 7–29%)         | 14%                           | 0/42                     |

Notes: N Nivolumab, I Ipilimumab, ORR Objective response rate, mUC Metastatic urothelial carcinoma, SCLC Small cell lung cancer, mCRC Metastatic colorectal cancer, OS Overall survival, OCSCC Squamous cell carcinoma of the oral cavity, MPR Major pathologic response, NSCLC Non-small cell lung cancer, EOC Epithelial ovarian cancer, MPM Malignant pleural mesothelioma, DCR Disease control rate
of life without chemotherapy. To improve the outcome of patients with advanced ESCC, we need to take a two-pronged approach. Firstly, we need to examine the role of potential therapy regimens in the efficacy of ESCC with a view to finding the most promising treatment modalities. Secondly, since the tumor microenvironment varies greatly among patients with ESCC, the same treatment suggests different efficacy in different patients. It is essential to select individualized treatments for every patient. Whether it is an immunotherapy plus chemotherapy regimen, a dual immunotherapy combination, or a novel option in the future, how to apply these regimens to the appropriate patients is a major concern. The robust biomarkers are warranted to help us screen out the most appropriate patients for different regimens, which achieve a favorable prognosis and avoid unnecessary side effects for patients with ESCC. The patient’s physical tolerance and contraindications to treatments should also be considered. Personalized treatment and management have been the primary clinical concern for ESCC, which needs to be continuously improved.

Improving the clinical outcomes of advanced ESCC has been a formidable challenge. The results of CheckMate 648 comprehensively uncovered the function of nivolumab plus ipilimumab combination in advanced ESCC, which is a novel attempt at the de-chemotherapy regimen. Although this dual immunotherapy did not suggest very promising achievements in all populations, it still has favorable efficacy in patients with PD-L1 expression ≥1%. The findings provided valuable insights into the clinical management of advanced ESCC.

ACKNOWLEDGEMENTS
This work was supported by the Fundamental Research Funds for the Central Universities (3332018070), the National Key Basic Research Development Plan (2018YFC1312105), and the Beijing Natural Science Foundation (J200010).